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Abstract
Objective: Recent recommendations regarding indications of accelerated partial breast irradiation (APBI) have been
put forward for selected breast cancer (BC) patients. However, some treatment planning parameters, such as total
dose, are not yet well defined. The Institut Gustave Roussy has initiated a dose escalation trial at the 40 Gy/10
fractions/5 days and at a further step of total dose (TD) of 42 Gy/10 fractions/ 5 days. Here, we report early results
of the latest step compared with the 40 Gy dose level.
Methods and materials: From October 2007 to March 2010, a total of 48 pT1N0 BC patients were enrolled within
this clinical trial: 17 patients at a TD of 42 Gy/10f/5d and 31 at a TD of 40 Gy/10f/5d. Median follow-up was
19 months (min-max, 12–26). All the patients were treated by APBI using a technique with 2 minitangents and an
“enface” electrons delivering 20% of the total dose. Toxicities were systematically assessed at 1; 2; 6 months and
then every 6 months.
Results: Patients’ recruitment of 42 Gy step was ended owing to persistent grade 3 toxicity 6 months after APBI
completion (n=1). Early toxicities were statistically higher after a total dose of 42 Gy regarding grade ≥2 dry
(p=0.01) and moist (p=0.05) skin desquamation. Breast pain was also statistically higher in the 42 Gy step
compared to 40 Gy step (p=0.02). Other late toxicities (grade ≥2 fibrosis and telangectasia) were not statistically
different between 42 Gy and 40 Gy.
Conclusions: Early toxicities were more severe and higher rates of late toxicities were observed after 42 Gy/10
fractions/5 days when compared to 40 Gy/10 fractions/5 days. This data suggest that 40 Gy/10 fractions/ 5 days
could potentially be the maximum tolerance for PBI although longer follow-up is warranted to better assess late
toxicities.
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The current trend in early breast cancer (BC) is to
shorten overall treatment time either by hypofractio-
nated whole breast irradiation [1] or by accelerated par-
tial breast irradiation (APBI). Local control efficacy of
3D-conformal APBI compared to whole breast irradi-
ation is currently investigated through large clinical
trials, such as NSABP B-39/ RTOG-0413 phase III trial
[2] and RAPID trial [3]. Waiting for definitive results of
those clinical trials, the American and European Radi-
ation Oncology Societies (ASTRO and ESTRO) put for-
ward guidelines for selected group of patients with
breast cancer at low risk of local relapse for whom APBI
could be performed out of clinical trials [4,5]. Even
though 3D-conformal APBI is one of the most used
APBI technique due to its practicality [6], the optimal
total dose and fractionation is not yet well defined. A
dose escalation 3D-conformal APBI trial has been
initiated in 2003 at the Massachussetts General Hospital
(MGH) to assess the optimal total dose consisting in
delivering 32 Gy/8fractions (f) over 4 days; 36 Gy/9f
over 4½days; 40 Gy/10f over 5 days (“40 Gy step”). In
collaboration with the MGH, we extended this clinical
trial by the enrolment of patients in the 40 Gy step [7]
and in an additional and further step : 42 Gy in 10 BID
fractions over 5 days. We have recently reported the
40 Gy step ((7)) and here, we report early results of the
latest step comparing 42 Gy/10 f with the 40 Gy/10 f
dose level.
Methods and materials
Study population
From October 2007 to March 2010, 48 pT1N0 unifocal
BC patients were prospectively enrolled in an institu-
tional and national review board-approved phase II trial.
Patients eligibility has been already described in [7] and
they were treated 4 to 12 weeks after a breast conserva-
tive surgery with 3D-conformal APBI.
Stopping rules were any persistent and severe (grade
3) toxicities (fibrosis or fat necrosis) or persistent early
grade 3 toxicity occurring during the year that followed
APBI completion. 31 breast cancer patients were en-
rolled in the 40 Gy step; and only 17 breast cancer
patients in the 42 Gy step. Hence, per the trial stopping
rules, patients’ recruitment was ended owing to persist-
ent grade 3 toxicity 6 months after APBI completion
(n=1).
Treatment planning and toxicity assessment
Briefly, all patients underwent to computed tomography
(CT)-based 3D planning. The ipsilateral and contralat-
eral breast, left and right lungs and heart were con-
toured [8]. The clinical target volume (CTV) was
defined as the delineation of the visible lumpectomy
cavity and the surgical clips placed inside the lumpec-
tomy cavity [9-11]; planning target volume (PTV) as a
CTV expansion of 2.3 to 2.8 cm. The PTV for evaluation
(PTV_EVAL) was the PTV with exclusion of the anterior
chest wall/pectoralis muscles and the first 5 mm of tis-
sue under the skin and anterior chest wall/pectoralis
muscles (according to the definition by Vicini et al.
[12]). The technique used was a combination of photon
beams of 6 MV and electrons of 6 to 22 MeV. The dosi-
metric plan was performed using Dosigray 4.1.2.50 TPS
(Dosisoft) [11]. Normal tissue dose–volume constraints
were defined as followed: 50% of the non-targeted breast
volume had be less than 50% of the prescribed dose; the
PTV_EVAL-to-whole breast ratio had to be less than
25%; and a limited dose was to be received by heart and
lungs. The lung volume dose constraints used were as
follows: <3% at 20 Gy, <10% at 10 Gy, and <20% at 5 Gy
[13]. Two successive total doses were prospectively
assessed: 40 Gy in 10 BID fractions over 5 days and
42 Gy in 10 BID fractions over 5 days, with a minimum
interfraction interval of 6 hours.
Statistical methods
Patients and tumors characteristics were compared
with the Wilcoxon test between each steps (40 Gy and
42 Gy). Dosimetric data of 40 Gy and 42gy steps were
compared with the Wilcoxon test.
Table 1 Patients and tumor characteristics (Abbreviation:
ER=estrogen receptor; PR=progesteron receptor)
42 Gy step
(n=17)
40 Gy step
(n=31)
Median age (years)(min-max) 67 (52–76) 65 (53–79)
Median tumor size (mm) (min-max) 10 (4–20) 11 (5–20)
Histology
Invasive ductal carcinoma (IDC) 82% 90%
Mucinous/tubular/other invasive carcinoma 6% -
Ductal Carcinoma In Situ (DCIS) 12% 10%
Nodal status
pN0 100% 100%
Scarff & Bloom histology grade
1 44% 64%
2 38% 32%
3 13% 4%
ER status
Positive 100% 100%
PR status (+)
Positive 69% 77%
Negative 31% 23%
Her2 status
Negative 100% 100%
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APBI; then 1, 2, 6 months after APBI completion and
further every 6 months. Toxicities were scored according
to the RTOG scale: grade 0 for none; grade 1 for mild;
grade 2 for moderate; grade 3 for severe; and grade 4 for
fatal toxicities. Toxicities incidences (by type and global),
estimated for each of the 2 total doses, were plotted with
Kaplan Meier incidence curves and compared with a
log-rank test.
Results
Patients and tumor characteristics are listed in Table 1.
Median follow-up was 19 months (min-max, 12–26) in
the 42 Gy step vs 32 months (min-max, 23–40) in the
40 Gy step. Mean age was 67 years (min-max, 52–76).
Median tumor size was 10 mm (min-max, 4–20). En-
rolled patients had mainly pT1N0 invasive ductal carcin-
oma (82%), positive hormone receptors, negative Her2
overexpression.
Planning target volume and normal tissue dosimetry
PTV_EVAL coverage was adequate with a mean dose to
the PTV_EVAL at 43.7 Gy (range, 43.1 – 44.4 Gy). Mean
breast V20Gy was at 41.6% (range, 15.4% – 55.2%).
Mean non-target breast V42Gy and V20Gy were at 6%
(range, 1.6%–11.9%) and 30.9% (range, 12.5%-44.5%), re-
spectively. Mean ipsilateral lung dose was 1.4 Gy (range,
1.0–1.8 Gy), and the V20 Gy was 0.2% (range, 0.0% –
1.0%). The mean heart dose was 1.1 Gy (range, 1.0–
1.3 Gy). No significant difference was seen between dosi-
metric parameters of 40 and 42 Gy steps except for a
higher V5Gy in the heart in the 40 Gy step (p=0.05).
Other dosimetric characteristics are listed in Table 2.
Early side effects for 42 Gy cohort (Table 3 and Figure 1)
Although patients cohort is smaller than those in 40 Gy
step, patients had more grade 2 erythema two months
after APBI completion (n=6/17; p=0.14), but was not
statistically significant when compared to 40 Gy step.
On the contrary, patients who were enrolled in the
42 Gy step had statistically more grade 2 moist des-
quamation (p=0.05); and had statistically more grade
2 dry desquamation (p=0.01) at early time points (1
and 2 months after APBI completion).
Late toxicities increased with higher total dose and
occurred earlier (at 6 months). Grade≥2 telangiectasia
Table 2 Dosimetric characteristics at the 42 Gy and 40 Gy step
Characteristic 42 Gy (n=17) 40 Gy (n=31 patients, 32 tumors)
Median Min - max Median Min - max
PTV coverage
V100% 99 97 - 100 99 95 - 100
V95% 100 100 - 100 100 99 - 100
V90% 100 100 - 100 100 99 - 100
Ipsilateral breast
V32 Gy (%) 35 13 - 48 40 21 - 50
V24 Gy (%) 39 15 - 53 46 23 - 54
V16 Gy (%) 43 16 - 57 49 24 - 57
V8 Gy (%) 54 18 - 68 55 26 - 75
Non target breast
V40 Gy (%) 10 3 - 18 8 3 - 18
V32 Gy (%) 25 10 - 35 29 6 - 38
V20 Gy (%) 32 12 - 44 35 8 - 45
V10 Gy (%) 44 14 - 60 44 11 - 63
Ipsilateral lung
V20 Gy (%) 0 0 - 1 0 0 - 1
V10 Gy (%) 0 0 - 2 1 0 - 6
V5 Gy (%) 3 0 - 5 4 0 - 12
Heart
V20 Gy (%) 0 0 - 0 0 0 - 0
V10 Gy (%) 0 0 - 0 0 0 - 1
V5 Gy (%) 0 0 - 1 1 0 - 4
left breast cancer, n=9 left breast cancer, n=13
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M1 M2 M6 M12 M18 M24
Early toxicities
Erythema 42 Gy (n=17) (n=17) (n=17) (n=17) (n=17) (n=17)
Grade 0 3 7 17 16 17 17
Grade 1 7 3 - 1 - -
Grade 2 4 6 - - - -
Unknown 3 1 - - - -
40 Gy (n =31) (n =31) (n=31) (n=31) (n=31) (n=31)
Grade 0 10 10 26 31 31 31
Grade 1 13 18 5 - - -
Grade 2 8 3 - - - -
Unknown - - - - - -
Dry desquamation 42 Gy (n=17) (n=17) (n=17) (n=17) (n=17) (n=17)
Grade 0 10 11 16 17 17 17
Grade 1 2 1 1 - - -
Grade 2 2 4 - - - -
Unknown 3 1 - - - -
40 Gy (n =31) (n =31) (n=31) (n=31) (n=31) (n=31)
Grade 0 19 26 31 31 31 31
Grade 1 4 3 - - - -
Grade 2 2 - - - - -
Unknown 6 2 - - - -
Moist desquamation 42 Gy (n=17) (n=17) (n=17) (n=17) (n=17) (n=17)
Grade 0 13 15 17 17 17 17
Grade 1 - - - - - -
Grade 2 1 1 - - - -
Unknown 3 1 - - - -
40 Gy (n =31) (n =31) (n=31) (n=31) (n=31) (n=31)
Grade 0 24 28 31 31 31 31
Grade 1 1 1 - - - -
Grade 2 - - - - - -
Unknown 6 2 - - - -
Late toxicities
Fibrosis or retraction 42 Gy (n=17) (n=17) (n=17) (n=17) (n=17) (n=17)
Grade 0 17 17 6 4 1 -
Grade 1 - - 7 10 6 5
Grade 2 - - 3 2 3 1
Grade 3 - - 1 1 - -
Unknown - - - - 7 11
40 Gy (n =31) (n =31) (n=31) (n=31) (n=31) (n=31)
Grade 0 31 30 23 19 9 8
Grade 1 - 1 5 10 15 19
Grade 2 - - 2 1 3 2
Grade 3 - - - 1 - -
Unknown - - 1 - 4 2
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in the 42 Gy versus 1/31 (3.2%) for the 40 Gy and
increased with time (30% in the 42 Gy versus 6% for
the 40 Gy at 18 months). Grade≥2 breast fibrosis was
observed in 2/31 (6.5%) of 40 Gy-patients and in 4/17
(24%) of 42 Gy-patients at 6 months. Similarly, grade≥
2 breast fibrosis was reported at 18 months in 3/31
(10%) of 40 Gy-patients and in 3/17 (18%) of 42 Gy-
patients. Hence, cosmetic results assessed by physicians
were considered as fair in 3/13 patients at 18 months
in the 42 Gy step whereas in the 40 Gy step was 2/26
patients. However grade ≥2 toxicities between 40 Gy
and 42 Gy steps were not statistically different except
for breast pain (p=0.02). Patients treated at the 42 Gy
step indeed observed more grade ≥2 breast pain (3/17
patients) rather than those treated at the 40 Gy step
(4/31 patients), the difference was statistically signifi-
cant (p=0.02).
Discussion
A higher total dose of 42 Gy delivered by 3D-conformal
APBI showed adequate treatment planning and did not
increase organs at risk exposure when compared to
other 3D-conformal APBI using lesser total dose [7].
Early tolerance was less suitable after a total dose of
42 Gy with higher risk of dry or moist skin desquam-
ation. In addition, even though patients’ enrollment was
ended owing to persistent grade 3 toxicity 6 months
after APBI completion, all late grade ≥2 toxicities were
not statistically different between 40 and 42 Gy steps ex-
cept for breast pain.
Many APBI clinical trials are currently in progress
using 3D-conformal radiotherapy and using different
total doses and fractionations. A dose escalation phase II
trial has been initiated at IGR in 2007 to assess the max-
imal dose tolerance.
Biologic effects in terms of tumor control and normal
tissue reactions are estimated through biologically effect-
ive dose (BED) values. The BED values for APBI sche-
dules should be interpreted by taking into account that
the linear quadratic model is not enough adequate to ac-
curately assess accelerated and bifractionated irradiation
schedule. Hence, a total dose of 42 Gy in 10 fractions
over 5 days achieved a BED value at 68.5 Gy for acute
effects as erythema (α/β ratio equal to 8). In the present
study, the 42 Gy step conferred higher risk of acute skin
Table 3 Early and late toxicity (Continued)
Breast pain 42 Gy (n=17) (n=17) (n=17) (n=17) (n=17) (n=17)
Grade 0 9 6 6 5 3 2
Grade 1 5 10 7 9 6 2
Grade 2 - - 3 2 3 2
Grade 3 - - 1 1 - -
Unknown 3 1 - - 5 11
40 Gy (n =31) (n =31) (n=31) (n=31) (n=31) (n=31)
Grade 0 11 14 17 16 12 12
Grade 1 11 13 11 10 10 12
Grade 2 3 2 2 5 4 5
Grade 3 - - - - - -
Unknown 6 2 1 - 5 2
Telangiectasia 42 Gy (n=17) (n=17) (n=17) (n=17) (n=17) (n=17)
Grade 0 17 17 15 12 7 4
Grade 1 - - - - 2 1
Grade 2 - - 1 3 2 -
Grade 3 - - 1 2 1 1
Unknown - - - - 5 11
40 Gy (n =31) (n =31) (n=31) (n=31) (n=31) (n=31)
Grade 0 29 30 29 25 19 17
Grade 1 1 - - 3 3 6
Grade 2 1 1 1 2 5 6
Grade 3 - - - - - -
Unknown - - 1 1 4 2
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3 8 14 21 22 31
2 6 17
0%
20%
40%
60%
80%
100%
0 6 12 18 24 30months
40 Gy
42 Gy
logrank test: p = 0.14
Incidence of dry skin 
3 9 17 28 29 31
2 3 9 17
0%
20%
40%
60%
80%
100%
0 6 12 18 24 30months
40 Gy
42 Gy
logrank test: p = 0.01
Incidence of moist skin 
3 9 17 30 31 31
2 4 12 17
0%
20%
40%
60%
80%
100%
0 6 12 18 24 30months
40 Gy
42 Gy
At risk
logrank test: p = 0.05
Incidence of fibrosis
16 23 27 29 29 31
1 8 13 17 17
0%
20%
40%
60%
80%
100%
0 6 12 18 24 30months
40 Gy
42 Gy
At risk
logrank test: p = 0.32
Incidence of pain
14 18 23 24 27 31
1 5 12 17 17
0%
20%
40%
60%
80%
100%
0 6 12 18 24 30months
40 Gy
42 Gy
At risk
logrank test : p = 0.02
Incidence of telangectasia
18 23 27 30 30 31
1 8 15 17 17
0%
20%
40%
60%
80%
100%
0 6 12 18 24 30months
40 Gy
42 Gy
At risk
logrank test: p = 0.15
7 9 12 14 17 31
1 3 6 17
0%
20%
40%
60%
80%
100%
0 6 12 18 24 30months
40 Gy
42 Gy
At risk
logrank test: p = 0.07
Figure 1 Incidence of grade ≥2 toxicities.
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grade 1–2 dry desquamation. Others non invasive APBI
studies reported lower rate of acute radio-induced
effects as the authors used irradiation scheme with lower
BED. For instance, Livi and colleagues described 5% of
grade 1 and 0.8% grade 2 acute skin toxicities after
IMRT-APBI delivering a total dose of 30 Gy in 5 frac-
tions over one week (BED value at 44.2 Gy for acute
effects) [14]. Other study reported similar results to
those form Livi and colleagues, with 6% of grade 2 acute
skin toxicities occurred after a total dose of 38 Gy in 10
BID fraction over 5 days (BED value of 58.8 Gy) [15].
Similarly, Vicini and colleagues observed 43% of mild
erythema and 12% of mild dry desquamation after 3D-
conformal APBI (total dose of 38.5 Gy/ 10f/ 5d, i.e. BED
value of 59.8 Gy).
When BED values were estimated for late toxicities, low
α/β ratio is usually used (α/β ratio=2). Even though a
longer median FU of this study is warranted to accurately
assess the role of 42 Gy in 10 fractions in the development
of late toxicities, grade 1–2 breast pain was observed in
70% of patients and all grade 3 late toxicities in 11.8% of
patients (fibrosis, telangiectasia, severe breast pain; n=3)
for an estimated BED value at 132 Gy. In recent report of
Vicini and colleagues [16,4]; the authors described 30.8%
of grade 1–2 breast pain and 4% of grade 3 late toxicities
for a BED value estimated at 112.6 Gy.
Most of APBI clinical trials or prospective studies
used an external beam irradiation (3D-conformal or
intensity-modulated radiotherapy) with a total dose of
38.5 Gy and attempted to determine dosimetric factors
predicting late toxicity occurrence. Despite treatment
planning and delivery were conform to the National
Surgical Adjuvant Breast and Bowel Project B-39/
Radiation Therapy Oncology Group 0413 protocol
(NSABP-B39/ RTOG 0413), none risk factor was
retrieved. Hence Hepel and colleagues have initially
described the maximum dose within the breast,
PTV_EVAL and the breast volume exposure in propor-
tion to the overall nontarget breast volume (V5–80) as
risk factors of late toxicities occurrence (median follow-
up of 15 months) [17]. At the opposite, recent initial
results of RTOG 0319 did not get any risk factors of late
toxicities after a longer median follow-up (36 months)
[18]. Here, using a single institution experience and
using the same 3D-conformal APBI technique, we
showed through a prospective clinical trial that increas-
ing total dose to a 42 Gy/ 10 fractions, BID could be a
risk factor of early toxicities such as grade ≥2 dry and
moist skin desquamation and of breast pain.
Conclusions
Optimal total dose and fractionation are still debated
even though most of APBI protocols use treatment
planning and delivery in accordance to the NSABP-B39/
RTOG 0413 protocol. The total dose of 42 Gy in 10 frac-
tions over 10 days is probably not optimal and can cause
significant acute toxicity. Optimal total dose for efficacy
and for tolerance would be determined through a larger
cohort within a dose escalation phase II trial with ma-
ture data [19] and a longer follow-up is warranted to
prospectively assess long-term toxicity.
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